Market Introduction
The usage of electronic Clinical Outcome Assessment (eCOA) is a push towards adapting to the ‘new normal’ as it is a method to gather patient data electronically through the use of technology such as smart home devices, handheld monitors, wearables, e-diaries, tablets and web servers to allow the stakeholders in the trials (patients, healthy volunteers, investigators and caregivers) to report outcomes directly and digitally. Although historically COA was only related to the evaluation of Patient-Related Outcomes (PRO), the FDA has now broadened the definition to include PerfO, ClinRO and ObsRO along with PRO. In simple terms, when the above parameters are reported electronically, they fit under the eCOA spectrum.
eCOA/ePRO platform has substantial benefits for sponsors and CROs, as it reduces administrative burden, mitigates cost, and speeds trials. Such a system shows strong results with fewer errors and discrepancies, improved data quality, clearer signals, and standardized, accurate studies. The increasing adoption of EHR, and government regulations mandating maintain health records is driving the growth of the market.
Thus, a growing demand for clinical trials is expected to create a significant demand for ePRO, ePatient Diaries, and eCOA in the coming years, which is further anticipated to drive the ePRO, ePatient Diaries, and eCOA market.
The DIA China Digital Health Community organized a series of Remote Digital Clinical Trials During COVID-19 Pandemic online seminars to increase global interest in remote clinical trials and digital clinical trial resources. Veteran clinicians and researchers presented real-life examples of remote clinical trial and digital trial technology implementations in China and strategies and plans based on their experiences. Sponsors and CROs have been able to preserve their business continuity in China by using remote clinical trials to overcome the difficulties of conducting conventional clinical trials faced by the COVID-19 pandemic (impacting on-site subject visits, data monitoring, and drug delivery). However, since these trials are just getting underway in China, it's important to optimize the effect of these technologies and services, and relevant regulations should evolve to support these developments accordingly. Thus, ePRO, e-Patient Diaries, and eCOA market is moderately impacted due to COVID -19.
Market Overview and Dynamics
The ePRO, ePatient Diaries, and eCOA market in Asia Pacific is expected to grow from US$ 348.8 million in 2021 to US$ 964.2 million by 2028; it is estimated to grow at a CAGR of 15.6% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA's adoption in the coming years. Mobile-enabled portals make it easier for patients to communicate with healthcare providers and allow patients to check test results, and review their medical record using smartphones. Also, market players are launching products for mobile applications, which will further boost the market's growth. For instance, in December 2020, Mednet, a healthcare technology company, announced its latest software release featuring expanded electronic patient reported outcomes (ePRO) capabilities. The new ePRO module is designed to increase patient engagement and enable remote participation, an increasingly important requirement in the COVID-19 era, while significantly improving the user experience for clinical staff as well as study participants. The new Mednet module is the result of a year-long development process designed to improve the user experience of Mednet's ePRO capability, including fully optimized module for mobile tablets. Also, in Nov 2020, Medable launched telehealth eCOA technology, which reportedly enables outcome assessment to be conducted remotely via web and mobile.
Key Market Segments
In terms of type of solution, the e-clinical outcome assessments segment accounted for the largest share of the Asia Pacific ePRO, ePatient Diaries, and eCOA market in 2020. In terms of modality, the mobile devices segment held a larger market share of the ePRO, ePatient Diaries, and eCOA market in 2020. In terms of end user, the cinical trial sponsors segment held a larger market share of the ePRO, ePatient Diaries, and eCOA market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the EPRO, ePatient Diaries, and eCOA market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are ERT Clinical, ArisGlobal LLC, The Diary Pte. Ltd, ICON PLC, PAREXEL INTERNATIONAL CORPORATION, Anju Software, Inc., Kayentis, Bracket Global LLC, Dassault Systèmes SE, and CRF Health.
Reasons to buy report
ASIA PACIFIC EPRO, EPATIENT DIARIES, AND ECOA MARKET SEGMENTATION
By Type of Solution
By Modality
By End User
By Country
Companies Mentioned